Patents by Inventor Gillian Clark

Gillian Clark has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10688111
    Abstract: The invention provides liquid formulations of compounds that act at sulfonylurea receptors that are suitable for intravenous and intra-arterial infusion. Compounds active at a sulfonylurea receptor include glibenclamide, tolbutamide, repaglinide, nateglinide, meglitinide, midaglizole, LY397364, LY389382, glyclazide, and glimepiride. Liquid formulations may be concentrated solutions suitable for storage; may be diluted (e.g., dilution of 1:1 or 1:1.2) suitable for bolus injections, and may be further diluted (e.g., dilution of 1:10 or 1:20 or more) for intravenous and intra-arterial infusion over an extended period of time. For example, a liquid formulation may include at least about 0.05 mg/ml glibenclamide in a water-based solution including 40% polyethylene glycol 300, 10% Ethanol, 50% water, at about pH 9. The solution may include a buffer, and is suitable for storage in refrigerator or at room temperature. This solution may be diluted 1:1, or more (e.g., 1:20) without precipitation of the glibenclamide.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: June 23, 2020
    Assignee: Biogen Chesapeake LLC
    Inventors: Sven Jacobson, Gillian Clarke, Rajinder Matharu
  • Patent number: 9895728
    Abstract: A method for desalinating and recycling the brine exiting a salt cavern. This method reduces the overall make-up water demand to wash a salt cavern, eliminates the brine disposal well and controls the cavern growth rate during disposal operations. The method includes the steps of: a) desalinating brine emerging from the salt cavern, and creating a stream of saline water, a stream of non-saline water and a stream of salt; b) recycling the stream volumes and combining the stream of non-saline and saline water with make-up water, thereby reducing demand for make-up water, c) pumping the salinated water into the salt cavern, and controlling the rate of growth of the salt cavern while disposing of wastes in the cavern, and repeating steps a) and b) substituting the make-up water with a waste mixture.
    Type: Grant
    Filed: June 13, 2016
    Date of Patent: February 20, 2018
    Assignee: ATHABASCA OIL CORPORATION
    Inventors: Tad Jason Kondo, Gillian Clark, Bryan Armand Vandal
  • Publication number: 20170216321
    Abstract: The invention provides liquid formulations of compounds that act at sulfonylurea receptors that are suitable for intravenous and intra-arterial infusion. Compounds active at a sulfonylurea receptor include glibenclamide, tolbutamide, repaglinide, nateglinide, meglitinide, midaglizole, LY397364, LY389382, glyclazide, and glimepiride. Liquid formulations may be concentrated solutions suitable for storage; may be diluted (e.g., dilution of 1:1 or 1:1.2) suitable for bolus injections, and may be further diluted (e.g., dilution of 1:10 or 1:20 or more) for intravenous and intra-arterial infusion over an extended period of time. For example, a liquid formulation may include at least about 0.05 mg/ml glibenclamide in a water-based solution including 40% polyethylene glycol 300, 10% Ethanol, 50% water, at about pH 9. The solution may include a buffer, and is suitable for storage in refrigerator or at room temperature. This solution may be diluted 1:1, or more (e.g., 1:20) without precipitation of the glibenclamide.
    Type: Application
    Filed: April 8, 2016
    Publication date: August 3, 2017
    Inventors: Sven Jacobson, Gillian Clarke, Rajinder Matharu
  • Publication number: 20160361741
    Abstract: A method for desalinating and recycling the brine exiting a salt cavern. This method reduces the overall make-up water demand to wash a salt cavern, eliminates the brine disposal well and controls the cavern growth rate during disposal operations. The method includes the steps of: a) desalinating brine emerging from the salt cavern, and creating a stream of saline water, a stream of non-saline water and a stream of salt; b) recycling the stream volumes and combining the stream of non-saline and saline water with make-up water, thereby reducing demand for make-up water, c) pumping the salinated water into the salt cavern, and controlling the rate of growth of the salt cavern while disposing of wastes in the cavern, and repeating steps a) and b) substituting the make-up water with a waste mixture.
    Type: Application
    Filed: June 13, 2016
    Publication date: December 15, 2016
    Applicant: ATHABASCA OIL CORPORATION
    Inventors: Tad Jason KONDO, Gillian CLARK, Bryan Armand VANDAL
  • Patent number: 8440616
    Abstract: The present invention provides a method comprising administering to a patient suffering from an endocrine disorder characterized by partial endogenous growth hormone activity or signaling an amount of insulin-like growth factor-1 (IGF-1) and an amount of growth hormone (GH) that in combination are effective to improve growth or metabolism in the patient, where the patient receives IGF-1 in a single daily administration and receives GH in a single daily administration, and where the single administrations are administered to the patient substantially contemporaneously each day.
    Type: Grant
    Filed: March 12, 2012
    Date of Patent: May 14, 2013
    Assignee: Tercica, Inc.
    Inventor: Gillian Clark
  • Publication number: 20120232009
    Abstract: The present invention provides a method comprising administering to a patient suffering from an endocrine disorder characterized by partial endogenous growth hormone activity or signaling an amount of insulin-like growth factor-1 (IGF-1) and an amount of growth hormone (GH) that in combination are effective to improve growth or metabolism in the patient, where the patient receives IGF-1 in a single daily administration and receives GH in a single daily administration, and where the single administrations are administered to the patient substantially contemporaneously each day.
    Type: Application
    Filed: March 12, 2012
    Publication date: September 13, 2012
    Inventors: Ross G. Clark, Gillian Clark
  • Patent number: 8158582
    Abstract: The present invention provides methods and compositions for increasing the growth rates, alleviating the symptoms, or improving the metabolism of human patients having an endocrine disorder characterized by partial endogenous growth hormone activity or signaling. The invention provides a method comprising administering to a patient suffering from an endocrine disorder characterized by partial endogenous growth hormone activity or signaling an amount of insulin-like growth factor-1 (IGF-1) effective to improve metabolism in the patient, where the patient receives IGF-1 in a single daily administration.
    Type: Grant
    Filed: June 1, 2006
    Date of Patent: April 17, 2012
    Assignee: Tercica, Inc.
    Inventors: Ross G. Clark, Gillian Clark, legal representative
  • Patent number: 8108149
    Abstract: The present invention provides standard deviation score (SDS) calculators, which SDS calculators are useful for transforming insulin-like growth factor-1 (IGF-1) concentrations to IGF-1 standard deviation scores. In one embodiment, IGF-1 blood levels are calculated so as to take into account IGFBP-3 blood levels (and, optionally, IGF-2 blood levels) to provide an IGF-1 production rate, which can be used to calculate an IGF-1 production rate SDS. The IGF-1 SDS and IGF-1 production rate SDS are particularly useful in assessing the stimulated rate of IGF-1 production in response to, for example, growth hormone therapy.
    Type: Grant
    Filed: August 29, 2005
    Date of Patent: January 31, 2012
    Assignee: Tercica, Inc.
    Inventors: Ross Graham Clark, Gillian Clark, legal representative, George M. Bright, Sam Liao
  • Publication number: 20110229055
    Abstract: A phantom for determining the alignment of two or more imaging apparatuses. The phantom comprises a vessel, wherein a cavity is defined by the inner surfaces of the vessel. The cavity is for holding a fluid therein. Two or more rods extend through the cavity, the rods being non-parallel with one another.
    Type: Application
    Filed: June 23, 2008
    Publication date: September 22, 2011
    Applicant: KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST
    Inventor: Gillian Clarke
  • Publication number: 20110034560
    Abstract: The invention provides liquid formulations of compounds that act at sulfonylurea receptors that are suitable for intra-venous and intra-arterial infusion. Compounds active at a sulfonylurea receptor include glibenclamide, tolbutamide, repaglinide, nateglinide, meglitinide, midaglizole, LY397364, LY389382, glyclazide, and glimepiride. Liquid formulations may be concentrated solutions suitable for storage; may be diluted (e.g., dilution of 1:1 or 1:1.2) suitable for bolus injections, and may be further diluted (e.g., dilution of 1:10 or 1:20 or more) for intravenous and intra-arterial infusion over an extended period of time. For example, a liquid formulation may include at least about 0.05 mg/ml glibenclamide in a water-based solution including 40% polyethylene glycol 300, 10% Ethanol, 50% water, at about pH 9. The solution may include a buffer, and is suitable for storage in refrigerator or at room temperature. This solution may be diluted 1:1, or more (e.g., 1:20) without precipitation of the glibenclamide.
    Type: Application
    Filed: January 29, 2009
    Publication date: February 10, 2011
    Inventors: Sven Jacobson, Gillian Clarke, Rajinder Matharu
  • Publication number: 20100137200
    Abstract: The present invention provides methods and compositions for increasing the growth rates, alleviating the symptoms, or improving the metabolism of human patients having an endocrine disorder characterized by partial endogenous growth hormone activity or signaling. The invention provides a method comprising administering to a patient suffering from an endocrine disorder characterized by partial endogenous growth hormone activity or signaling an amount of insulin-like growth factor-1 (IGF-1) effective to improve metabolism in the patient, where the patient receives IGF-1 in a single daily administration.
    Type: Application
    Filed: June 1, 2006
    Publication date: June 3, 2010
    Inventors: Ross G. Clark, Gillian Clark
  • Publication number: 20090293540
    Abstract: Transformed The Mind Jewellery is a unique and powerful tool for healing. The basic understanding of this unit that it uses multiple stimulus to provide touch healing through pulses and vibration, a phototherapeutic lighting system that interacts with the skin and of the being on the cellular level and beyond a sub-audible, subliminal message transferred through a speaker. This said message is the main program that allows the control of pulse light and sound to simultaneously stimulate the being of the wearer of this Jewellery. This unit draws in its information and overnight charge through a USB2.0 system. This charge is stored in the lithium ion batteries. A charge is transferred throughout the system. The Jewellery has a high draw for its small size, thus a placement of five lithium ion rechargeable batteries have been placed in the Jewellery piece.
    Type: Application
    Filed: May 29, 2008
    Publication date: December 3, 2009
    Inventor: Gillian Clark